A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Posttraumatic Neuralgia..

AstraZeneca

Status and phase: Completed; Phase 2

Conditions: Nerve Pain

Treatments: Drug: AZD2423; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01200524

D2600C00012

Details and patient eligibility

About

A study to investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days treatment in patients with posttraumatic neuralgia.

Enrollment: 133 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provision of signed informed consent form
• Males and female patients aged 18 to 80 years
• Patients with neuropathic pain due to peripheral nerve injury caused by trauma or surgery

Exclusion criteria

• Other paint that may confound assessment of neuropathic pain
• History of treatment failure with more than three adequate trials of treatment for neuropathic pain
• Central neuropathic pain conditions (caused by Central Nervous System injury/disease, eg. Stroke)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

133 participants in 3 patient groups, including a placebo group

AZD2423, 20mg

Experimental group

Treatment:

Drug: AZD2423

Drug: AZD2423

AZD2423, 150 mg

Experimental group

Treatment:

Drug: AZD2423

Drug: AZD2423

Placebo

Placebo Comparator group

Description:

Tablet to match the 20 mg and 50 mg AZD2423 active tablet

Treatment:

Drug: Placebo